This site is intended for healthcare professionals outside the U.S.
The MAPP survey was an extensive look at the unmet needs in psoriasis and psoriatic arthritis, and how these diseases impact patients’ lives. 3426 patients across 7 countries, as well as 781 rheumatologists and dermatologists in North America, were interviewed, all managed by an academic steering committee of thought leaders in dermatology and rheumatology.1
Subset of all patients surveyed. Overall, 24% of all patients said they had been prescribed a traditional oral medication for their disease (eg, cyclosporine, methotrexate, acitretin, or fumaric acid esters) at some point since their diagnosis; of these, 43% were receiving therapy and 57% had discontinued use.
MAPP, Multinational Assessment of Psoriasis and Psoriatic Arthritis; PDE4, phosphodiesterase type 4; PsA, psoriatic arthritis.
References: 1. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881. 2. Data on file, Celgene Corporation. 3. Ianculescu I, Weisman M.H. The role of methotrexate in psoriatic arthritis: what is the evidence? Clin Exp Rheumatol. 2015;33(Suppl. 93):S94-S97. 4. Mease P. Methotrexate in Psoriatic Arthritis. Bulletin of the Hospital for Joint Diseases. 2013;71(Suppl 1):S41-5. 5. Mease PJ. Spondyloarthritis: is methotrexate effective in psoriatic arthritis? Nat Rev Rheumatol. 2012;8(5):251-252. 6. Orbai A, Weitz J, Siegel EL, et al. Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis. J Rheumatol. 2014;41;2290-2294.
Please choose a country